Custom Search
News
Wednesday 12 December 2007
Novo Nordisk Reports Results From Liraglutide Study
Danish drugmaker Novo Nordisk’s final Phase III study of liraglutide, the once-daily human GLP-1 analogue for treatment of Type 2 diabetes, demonstrated favorable blood glucose control and body weight.
The study, which is part of Novo Nordisk’s LEAD program, included 746 patients who received one of two doses of liraglutide or 8 mg of glimepiride, a widely used oral antidiabetic medication.
At both doses tested, liraglutide provided statistically significantly better glucose control than glimepiride. Liraglutide patients also saw a reduction of body weight of between 3 and 4 kg, Novo Nordisk said.
The company expects to file for regulatory approval of liraglutide during the second quarter of 2008.